Health Bulletin 25/November/2022 - Video
Overview
Here are the top health news for the day:
Thirteen measles deaths reported in Mumbai
An eight-year-old boy from Govandi died on Thursday due to multi-organ dysfunction syndrome with bronchopneumonia at a civic hospital, taking the death toll in the area to seven. Mumbai has reported Thirteen measles deaths so far. Meanwhile, the state's confirmed measles cases stood at 603. Of which, Malegaon civic corporation reported 62 cases and Bhiwandi civic corporation reported 36 cases.
Expensive drug worth $3.5 million a dose approved for Hemophilia B
Global biotechnology leader CSL has announced that the U.S. Food and Drug Administration (USFDA) has approved HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes. In the ongoing clinical trial, HEMGENIX reduced the rate of annual bleeds and 94 percent of patients discontinued factor IX prophylaxis and remained prophylaxis-free.
For more details, check out the link given below:
FIRST: CSL Bags USFDA Approval For HEMGENIX To Treat Hemophilia B
Patient dies from suspected drug reaction to Emcure Pharma's Orofer FCM
Drug maker Emcure Pharmaceuticals Ltd. has landed in trouble after a patient at Saifee Hospital administered iron supplement, Orofer FCM (ferric carboxymaltose) died of suspected Adverse Drug Reaction (ADR).
Acting on the complaint moved by the deceased's wife, the Food and Drugs Administration (FDA), Maharashtra issued a circular on Monday to recall all the injections (500 mg /10 ml) manufactured by Emcure Pharma from across the country. Orofer FCM injection is used to treat iron deficiency anaemia.
For more details, check out the link given below:
Speakers
